Amgen was the frontrunner among US Humira (adalimumab) biosimilar competitors in 2023, launching its Amjevita (adalimumab-atto) biosimilar at the end of January and gaining a five-month head start on its numerous rivals.
However, while this early launch delivered $51m in US sales during the two-month period that it was available in the first quarter of the year, figures just released by Amgen reflect a turnover drop of almost two-thirds for the product in the full second quarter of 2023, just before a slew of other biosimilars hit the market